Ignite Creation Date:
2025-12-25 @ 1:16 AM
Ignite Modification Date:
2026-01-01 @ 7:07 PM
Study NCT ID:
NCT00516893
Status:
COMPLETED
Last Update Posted:
2014-05-15
First Post:
2007-08-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Natalizumab High Titer Immunogenicity and Safety
Sponsor:
Biogen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
101MS201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Biogen Idec Medical Director
Old Organization:
Biogen Idec
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |